Search Results

What makes each drug type unique to therapeutic pharmacology? 3.

April 2022 Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage Matt Barnes appointed President of Heptares Therapeutics Ltd., and Head of UK R&D Tokyo, Japan and Cambridge

November 2021 "Cambridge’s Japanese-owned life sciences company Sosei Heptares has clinched a lucrative

Among those hitching their wagons to that star are Verily and Sosei Heptares, which have struck a research The financial details of the strategic collaboration weren’t released, but Sosei Heptares’ past two team-ups

collaborative neuroscience R&D program with Servier (France) and is the co-founder and CEO of Phrenix Therapeutics , a biotech spin-out from the Neuromedicines Discovery Centre that is developing next-generation therapeutics Prior to these roles this he was Head of Pharmacology at Heptares Therapeutics Ltd., a UK-based biotechnology These successes enabled the US$400M sale of Heptares Therapeutics Ltd. to the Sosei Group Corporation Prior to joining Heptares, Chris was a neuroscience researcher at GlaxoSmithKline, UK (1998-2009).

As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery

Join me to learn more about Chris’s work and his role in founding Heptares which was later acquired by Sosei and became Sosei Heptares . Chris Tate on the web LinkedIn ResearchGate Pubmed Google Scholar Sosei Heptares Wikipedia MRC Laboratory